Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Fate Therapeutics, Inc. (FATE)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
55.00+1.52 (+2.84%)
At close: 4:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close53.48
Open54.27
Bid52.53 x 800
Ask56.40 x 1300
Day's Range53.08 - 55.46
52 Week Range48.31 - 121.16
Volume1,101,151
Avg. Volume926,415
Market Cap5.164B
Beta (5Y Monthly)1.67
PE Ratio (TTM)N/A
EPS (TTM)-2.11
Earnings DateMay 05, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est109.83
  • Motley Fool

    3 Biotech Stocks That Can Double Your Money, According to Wall Street

    All three of these stocks could rise over 100% once stock-market sentiment falls in line with the opinions of investment-bank analysts.

  • GlobeNewswire

    Fate Therapeutics to Present at Upcoming Investor Conferences

    SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will present at the following upcoming investor conferences: Jefferies London Healthcare Conference available on demand on Thursday, November 18th, 2021 at 8:00 AM GMT, 3:00 AM ETPiper Sandler 33rd Annual H

  • GlobeNewswire

    Fate Therapeutics Announces Abstract Highlighting FT538 and FT573 Programs Selected for Presentation at SITC 2021 Annual Meeting Press Conference

    Company to Host Virtual Investor Event on Monday, November 15 SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Society for Immunotherapy of Cancer (SITC) Communications Committee selected an abstract featuring preclinical data from the Company’s FT538 and FT573 programs for showcase at the SITC 2021 A

Advertisement
Advertisement